Michael Krogh Jensen

Lygos, Inc. engages in the development of full-stack biological engineering platform. Its platform focuses on organic acid specialty chemicals and bio-monomers. The company was founded by Eric Steen, Jeffrey Dietrich, Jay D. Keasling, Leonard Katz, and J. L. Clem Fortman in 2010 and is headquartered in Berkeley, CA.

Roche Innovation Center Copenhagen A/S discovers and develops drugs for the treatment of oncology, metabolic diseases, and infectious diseases. The firm manufactures a pipeline of drug candidates that act selectively on disease-related ribonucleic acid to provide patients with novel treatments for both rare and common diseases. It produces pre-clinical and clinical assets for the treatment of a range of diseases including oncology, metabolic diseases, and infectious diseases. The company was founded by Matts Lundwall and Mikael Ørum on January 1, 1998 and is headquartered in Horsholm, Denmark.

Lawrence Berkeley National Laboratory engages on research of environmental studies, nanoscience, and quantitative biology, physics and nuclear energy. The lab is funded by the U.S. Department of Energy and managed by the University of California. It was founded in 1931 by Ernest Orlando Lawrence and is headquartered in Berkeley, CA.

LS Dissolution, Inc. engages in the production of petroleum replacement products and industrial chemicals. It offers chemical and fuel products. The company was founded by George M. Church, Christopher Somerville, Noubar B. Afeyan and Jay D. Keasling in 2005 and is headquartered in South San Francisco, CA.

Fragtmænd Holding A/S provides transportation and logistics services. The firm offers freight solutions, warehouse, and special services to companies in all industries. The company was founded on June 13, 2007 and is headquartered in Abyhoj, Denmark.

Part of Ventac Partners GmbH, Ventac Partners A/S provides life science consulting services. The company is based in Copenhagen, Denmark. The CEO of the Danish company is Mikael Ørum.

Demetrix, Inc. manufactures natural medicines. The company was founded by William Haseltine and Jay Keasling in 2015 and is headquartered in Emeryville, CA.

Next Stage Ventures ApS is a Danish company that focuses on researching and developing biotechnology products.

ResoTher Pharma is a privately held clinical-stage biotech company based in Copenhagen, Denmark. ResoTher Pharma focuses on developing compounds that induce inflammatory resolution in cardiovascular diseases. The Danish company's lead compound, RTP-026, has shown to have a profound effect on reducing infarction size and restoring cardiac function to a pre-infarction level. ResoTher Pharma's mission is to create novel medicines that benefit patients in need by addressing unmet needs in CVD inflammation through endogenous immune regulatory pathways. The company was founded in 2016 by Thomas Jonassen and is privately owned by a group of prominent Danish investors.

ADCendo ApS is a Danish company that is focused on developing antibody-drug conjugates (ADCs) to treat underserved cancers. The company is based in Humlebaek, Denmark. The company completed a series A extension financing round in 2023, which brought its funds to 82 million EUR to advance into clinical development. The investors in the company include Novo Holdings, Ysios Capital, Pontifax Venture Capital, RA Capital Management, HealthCap, and Gilde Healthcare. The company was founded in 2017 by Christoffer Nielsen, Henrik Stage. Michael Pehl has been the CEO of the company since 2021.

Napigen, Inc. is a biotechnology company that specializes in genome engineering of various organisms such as plants, microbes, and animals. The company is based in Wilmington, DE and Dr. Hajime Sakai has been the CEO since 2016. The company's technology targets mitochondria and chloroplasts, which are important for creating energy and producing biochemical molecules. The company's genome technology has broad applications in human and animal healthcare, agriculture, and industrial biotechnology. Napigen was founded in 2016 by a group of accomplished scientists, entrepreneurs, and investors including Dr. Hajime Sakai, Dr. Jay Keasling, Dr. Ganesh Kishore, and Dr. Roger Wyse.

ResVita Bio, Inc. is a company based in Berkeley, CA that aims to restore and maintain the vitality of the skin through the topical application of cellular therapies. ResVita Bio genetically programs living cells to repair disrupted skin and alleviate inflammation in various inflammatory skin diseases, including Netherton syndrome, atopic dermatitis, acne rosacea, and psoriasis. The company has received several awards, including the Bakar Innovation Fellowship, NIAMS SBIR Award, NIAID SBIR Award, and the AbbVie Golden Ticket at UC Berkeley's Bakar Labs. ResVita Bio is developing a safe and versatile skin probiotic platform through synthetic biology and metabolic engineering to continuously deliver therapies that directly treat inflammatory skin diseases, including Netherton syndrome, atopic dermatitis, chronic wound infection, and psoriasis. The company was founded by Amin Zargar and Jay D. Keasling, with Amin Zargar serving as the CEO since incorporation.